Calls Now Open
2022 ADDF-Harrington and 2023 Harrington UK Rare Disease Programs
We partner with for-profit organizations who share our mission of advancing scientific discoveries into medicines. These are socially responsible firms where there is an expectation of a return on investment. Impact investing partners work with us to commercialize technologies of Harrington Scholars, in conjunction with the Scholar's academic institution. This may include establishing a start-up company to attract funding and further advance the technology.
Access to the following companies can be facilitated by Harrington Discovery Institute or can be pursued directly. Contact us to learn more about becoming a partner or investor.
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative life sciences businesses in the UK, Europe and the US. Advent Life Sciences and Harrington partnered in 2021 to launch the Advent-Harrington Impact Fund, a global investment fund to advance breakthrough discoveries into novel treatments. This initiative combines the best of Advent Life Sciences with the Harrington Discovery Institute pipeline. Download press release.
For more information on opportunities to work with Advent-Harrington, contact us.
To learn more about Advent Life Sciences, visit their website.
BioMotiv is a mission-aligned partner of Harrington Discovery Institute, established under The Harrington Project for Discovery & Development in 2012. BioMotiv aligns drug development expertise, capital and pharmaceutical partners to accelerate discoveries into medicines.
Source: BioMotive website